The research led by the University of Pretoria, published in the Nature Communications journal this week, found that chemical compounds undergoing trials for the treatment of tuberculosis and cancer - the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109 - can kill the disease-causing parasite at a stage when it normally infects others.
The World Health Organisation said in November that deaths from malaria due to disruption during the coronavirus pandemic to services designed to tackle the mosquito-borne disease will far exceed those killed by COVID-19 in sub-Saharan Africa.